Big Health is using an upcoming educational webinar to drive greater adoption of its SleepioRx prescription digital therapeutic for insomnia among healthcare providers. The company is positioning digital CBT-I as a scalable way to expand access to evidence-based insomnia care while embedding SleepioRx into everyday clinical workflows.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Scheduled for May 15, 2026, the 30-minute session will be led by senior clinical leaders, including Big Health’s Chief Medical Officer and VP of Clinical Affairs. They plan to showcase the clinical evidence behind SleepioRx, present real-world patient case studies, and outline specific clinical use cases to build physician confidence.
The webinar will also address practical concerns around cost, coverage, and billing, which remain key hurdles for digital therapeutics adoption. Big Health intends to explain alternative referral and contracting models, such as direct contracts and embedded referrals, to make operational integration easier for providers.
This provider-focused education push signals a strategic shift toward deeper penetration in clinical settings rather than relying primarily on employer or direct-to-consumer channels. By clarifying reimbursement pathways and workflow fit, the company aims to reduce adoption friction and encourage more consistent prescribing of SleepioRx.
If successful, the initiative could support higher prescription volumes, more predictable recurring revenue, and stronger relationships with payers in the digital behavioral health market. Overall, the week’s developments underscore Big Health’s emphasis on clinical validation and integration as it seeks to scale SleepioRx and reinforce its competitive position in digital therapeutics for insomnia.